NR4A1 and breast cancer: It is noteworthy that approximately 10–30% of patients with breast cancer, regardless of their hormone receptor status, develop metastases to the lymph nodes or/and distant organs, making the design of an efficient treatment for this heterogeneous type of breast cancer a challenging task [11,12].